Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medeva

Executive Summary

Discussions of a cash offer for the firm "have now been terminated," Medeva announced Sept. 17. "The proposal received turned out to be at an opportunistic price which the board [of Medeva], advised by Lazard Brothers, had no hesitation in rejecting." Elan had been rumored to be the suitor (1"The Pink Sheet" Sept. 13, p. 4). At a Bear Stearns conference Sept. 15, Elan Exec VP-Business Development Michael Sember said that after several sizeable acquisitions in 1998, the company has been in a "breathing period...focusing on integrating these business units"

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel